Open AccessBroadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort
Author(s) -
Luke A. Granger,
Isabella Huettner,
Franka Debeljak,
Pontiano Kaleebu,
Mauro Schechter,
Giuseppe Tambussi,
Jonathan Weber,
José M. Miró,
Rodney E. Phillips,
Abdel Babiker,
David A. Cooper,
Martin Fisher,
Gita Ramjee,
Sarah Fidler,
John Frater,
Julie Fox,
Katie J. Doores
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002988
Subject(s) - seroconversion , virology , immunology , epitope , neutralization , neutralizing antibody , immunogen , aids vaccines , biology , hiv vaccine , cohort , antibody , viral load , human immunodeficiency virus (hiv) , medicine , monoclonal antibody , vaccine trial
Development of immunogens that elicit an anti-HIV-1 broadly neutralizing antibody (bnAb) response will be a key step in the development of an effective HIV-1 vaccine. Although HIV-1 bnAb epitopes have been identified and mechanisms of action studied, current HIV-1 envelope-based immunogens do not elicit HIV-1 bnAbs in humans or animal models. A better understanding of how HIV-1 bnAbs arise during infection and the clinical factors associated with bnAb development may be critical for HIV-1 immunogen design efforts.